Opus Genetics Inc (IRD)

$5.18 +0.06 (1.17%)
Market Cap 365.58M
Revenue (ttm) 14.20M
Net Income (ttm) -49.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -349.23%
Debt to Equity Ratio 0.00
Volume 1,659,800
Avg Vol 894,960
Day's Range N/A - N/A
Shares Out 71.40M
Stochastic %K 69%
Beta 0.62
Analysts Strong Sell
Price Target $10.20

Company Profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
focafoca99
focafoca99 May. 13 at 11:25 AM
$IRD presents at the RBC Capital Markets 2026 Global Healthcare Conference on May 19.
0 · Reply
signaljumper
signaljumper May. 11 at 4:50 PM
$IRD a Close above 5.5 and we will See the next Bull Leg Up
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 8:52 PM
$IRD!!! RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration’s (FDA) Rare Disease Evidence Principles (RDEP) program ❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️
1 · Reply
ifinitis
ifinitis May. 8 at 7:50 PM
$IRD Watch your stops, they want your shares! IMO
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 7:50 PM
$IRD!!! !!!!!! L O A D E M !!!!!!
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 5:20 PM
$IRD!!! Will Grind Right Back Up!!!
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 5:19 PM
$IRD!!! Best Be Adding Real Opportunity Here…
0 · Reply
Um8a123
Um8a123 May. 7 at 10:06 PM
$IRD This is getting ready for a run, easy 10z
0 · Reply
TruthTooPower
TruthTooPower May. 7 at 7:56 PM
$IRD!!! !!!!!!!! D O U B L E D I G I T S !!!!!!!
0 · Reply
ifinitis
ifinitis May. 5 at 8:34 PM
$IRD Last 5 short-term moving average merges have all resulted in upward movement. Good sign!
0 · Reply
Latest News on IRD
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

May 13, 2026, 7:00 AM EDT - 2 hours ago

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

Opus Genetics price target lowered to $11 from $12 at Citizens

2026-05-13T09:57:18.000Z - 3 hours ago

Opus Genetics price target lowered to $11 from $12 at Citizens

Opus Genetics reports Q1 EPS (75c), consensus (14c)

2026-05-12T12:00:32.000Z - 1 day ago

Opus Genetics reports Q1 EPS (75c), consensus (14c)

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 1 day ago

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

May 7, 2026, 4:30 PM EDT - 5 days ago

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

May 7, 2026, 7:00 AM EDT - 6 days ago

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program

2026-05-04T21:16:00.000Z - 8 days ago

Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

May 4, 2026, 4:30 PM EDT - 8 days ago

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics price target raised to $10 from $9 at B. Riley

2026-04-30T13:56:08.000Z - 12 days ago

Opus Genetics price target raised to $10 from $9 at B. Riley

Opus Genetics initiated with an Outperform at Citizens

2026-04-28T08:45:12.000Z - 15 days ago

Opus Genetics initiated with an Outperform at Citizens

Opus Genetics management to meet with Piper Sandler

2026-04-27T19:55:56.000Z - 15 days ago

Opus Genetics management to meet with Piper Sandler

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Apr 27, 2026, 8:00 AM EDT - 16 days ago

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Opus Genetics management to meet with B. Riley

2026-04-14T14:50:14.000Z - 4 weeks ago

Opus Genetics management to meet with B. Riley

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 10, 2026, 6:59 AM EDT - 4 weeks ago

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Apr 6, 2026, 7:00 AM EDT - 5 weeks ago

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T10:22:42.000Z - 6 weeks ago

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T10:10:51.000Z - 6 weeks ago

Opus Genetics initiated with an Overweight at Cantor Fitzgerald

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Mar 24, 2026, 7:00 AM EDT - 7 weeks ago

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Oppenheimer bullish on Opus Genetics, initiates with an Outperform

2026-03-16T11:41:19.000Z - 2 months ago

Oppenheimer bullish on Opus Genetics, initiates with an Outperform

Opus Genetics initiated with an Outperform at Oppenheimer

2026-03-16T10:32:04.000Z - 2 months ago

Opus Genetics initiated with an Outperform at Oppenheimer

Opus Genetics files to sell 7.37M shares of common stock for holders

2026-03-13T21:00:32.000Z - 2 months ago

Opus Genetics files to sell 7.37M shares of common stock for holders

Opus Genetics price target raised to $10 from $8 at Wedbush

2026-03-12T12:21:25.000Z - 2 months ago

Opus Genetics price target raised to $10 from $8 at Wedbush

Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year

2026-03-10T11:06:29.000Z - 2 months ago

Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Mar 3, 2026, 8:00 AM EST - 2 months ago

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Opus Genetics price target raised to $12 from $7 at BTIG

2026-03-02T12:45:49.000Z - 2 months ago

Opus Genetics price target raised to $12 from $7 at BTIG

Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1

2026-02-27T15:22:14.000Z - 2 months ago

Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Feb 27, 2026, 10:10 AM EST - 2 months ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics says FDA accepts sNDA for phentolamine ophthalmic solution 0.75%

2026-02-25T12:09:04.000Z - 2 months ago

Opus Genetics says FDA accepts sNDA for phentolamine ophthalmic solution 0.75%

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Feb 25, 2026, 6:59 AM EST - 2 months ago

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement

2026-02-13T12:40:37.000Z - 3 months ago

Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement

Opus Genetics Announces $25 Million Private Placement

Feb 13, 2026, 7:30 AM EST - 3 months ago

Opus Genetics Announces $25 Million Private Placement

Opus Genetics initiated with an Outperform at LifeSci Capital

2026-02-12T12:55:46.000Z - 3 months ago

Opus Genetics initiated with an Outperform at LifeSci Capital

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Feb 2, 2026, 8:00 AM EST - 3 months ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 27, 2026, 7:00 AM EST - 3 months ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Opus Genetics Transcript: 44th Annual J.P. Morgan Healthcare conference

Jan 15, 2026, 11:15 AM EST - 4 months ago

Opus Genetics Transcript: 44th Annual J.P. Morgan Healthcare conference

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Jan 8, 2026, 7:00 AM EST - 4 months ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 4:01 PM EST - 5 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 5 months ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Dec 9, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 20, 2025, 8:00 AM EST - 6 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 13, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Nov 6, 2025, 7:00 AM EST - 6 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Oct 2, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics Transcript: Study result

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Opus Genetics Transcript: Study result

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Sep 30, 2025, 7:00 AM EDT - 8 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 9 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 11 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Transcript: Investor update

Jun 26, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Transcript: Investor update

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 11 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 1 year ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 1 year ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 1 year ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

focafoca99
focafoca99 May. 13 at 11:25 AM
$IRD presents at the RBC Capital Markets 2026 Global Healthcare Conference on May 19.
0 · Reply
signaljumper
signaljumper May. 11 at 4:50 PM
$IRD a Close above 5.5 and we will See the next Bull Leg Up
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 8:52 PM
$IRD!!! RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration’s (FDA) Rare Disease Evidence Principles (RDEP) program ❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️
1 · Reply
ifinitis
ifinitis May. 8 at 7:50 PM
$IRD Watch your stops, they want your shares! IMO
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 7:50 PM
$IRD!!! !!!!!! L O A D E M !!!!!!
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 5:20 PM
$IRD!!! Will Grind Right Back Up!!!
0 · Reply
TruthTooPower
TruthTooPower May. 8 at 5:19 PM
$IRD!!! Best Be Adding Real Opportunity Here…
0 · Reply
Um8a123
Um8a123 May. 7 at 10:06 PM
$IRD This is getting ready for a run, easy 10z
0 · Reply
TruthTooPower
TruthTooPower May. 7 at 7:56 PM
$IRD!!! !!!!!!!! D O U B L E D I G I T S !!!!!!!
0 · Reply
ifinitis
ifinitis May. 5 at 8:34 PM
$IRD Last 5 short-term moving average merges have all resulted in upward movement. Good sign!
0 · Reply
rce4000
rce4000 May. 4 at 9:03 PM
$IRD Good news: https://ir.opusgtx.com/press-releases/detail/527/opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program
0 · Reply
signaljumper
signaljumper May. 4 at 7:35 PM
$IRD next Key Level is a Break and Close baove 5.50 then we will See new 52 week highs
0 · Reply
TruthTooPower
TruthTooPower May. 4 at 11:45 AM
$IRD!!! !!!!!!!!!DOUBLE DIGITS!!!!!!!!!!
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 10:50 PM
$IRD Current Stock Price: $5.13 Contracts to trade: $5.0 IRD May 15 2026 Call Entry: $0.50 Exit: $0.71 ROI: 43% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
signaljumper
signaljumper May. 1 at 4:00 PM
$IRD above 5.20 and we will move fast over the Last highs
0 · Reply
retro123
retro123 May. 1 at 12:34 AM
$IRD im surprised at the short interest in this and if i were in their shoes id be anxious rn
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 11:21 PM
$IRD Share Price: $5.11 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $1.10 – $1.37 Target Zone: $2.03 – $2.48 Potential Upside: 73% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TruthTooPower
TruthTooPower Apr. 30 at 9:41 PM
$IRD!!!
0 · Reply
TruthTooPower
TruthTooPower Apr. 30 at 9:41 PM
$IRD!!! Hell Yeah 🙌🙌🙌
0 · Reply
TruthTooPower
TruthTooPower Apr. 30 at 9:40 PM
$IRD!!! Told You!!!
0 · Reply
Um8a123
Um8a123 Apr. 30 at 8:01 PM
$IRD Still here and adding every dip
0 · Reply
TruthTooPower
TruthTooPower Apr. 30 at 8:01 PM
$IRD!!! Your Welcome!!! 🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓
0 · Reply